^
Association details:
| Biomarker: | MTAP negative |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Talzenna (talazoparib) (PARP inhibitor) + MS023 (PRMT1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells
Published date:
03/10/2021
Excerpt:
The combination of MS023 and the PARP inhibitor BMN-673 (Talazoparib) demonstrated strong synergistic interaction at low nanomolar concentrations in MTAP-negative NSCLC cell lines A549, SK-LU-1 and HCC4006...combining PARP inhibitors and type I PRMT inhibitors represents a new therapeutic opportunity for MTAP-negative NSCLC...
DOI:
10.1186/s13148-021-01037-1
